双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002038 双鹭药业

开盘竞价 02-09 09:30:00

{"stockData":{"symbol":"002038","market":"SZ","secType":"STK","nameCN":"双鹭药业","latestPrice":6.6,"timestamp":1770600027000,"preClose":6.6,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":852000000,"shares":1027000000,"eps":0.0816,"marketStatus":"开盘竞价","change":0,"latestTime":"02-09 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":6.6,"askSize":2634,"bidPrice":6.6,"bidSize":2634,"shortable":0,"etf":0,"ttmEps":0.0816,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":1,"adr":0,"adjPreClose":6.6,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":7.26,"lowLimit":5.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1027350000,"isCdr":false,"pbRate":1.19,"roa":"--","peRate":80.882353,"roe":"2.5%","epsLYR":-0.07,"committee":-0.149637,"marketValue":6781000000,"turnoverRate":0,"status":2,"floatMarketCap":5623000000},"requestUrl":"/m/hq/s/002038","defaultTab":"news","newsList":[{"id":"2608477428","title":"双鹭药业：奥司他韦可用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608477428","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608477428?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:12","pubTimestamp":1770102735,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，问下公司在抗流感方面有哪些药物，预防流感有哪些药物，glp-1年复一年，现在还需要多少年？？？双鹭药业回复：您好，公司产品奥司他韦可用于流感治疗，此外公司产品胸腺五肽、白介素-2为免疫增强剂，可提升免疫力预防流感；长效GLP-1类产品度拉糖肽目前已提交上市申请，待受理。产品注册检验合格。如有最新进展公司会适时交流。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002038","BK0028","BK0239"],"gpt_icon":0},{"id":"2608106847","title":"双鹭药业：该公司不是公司子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2608106847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608106847?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:06","pubTimestamp":1770102390,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：福建双鹭医药有限公司是否为子公司？双鹭药业回复：您好，该公司不是公司子公司。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002038"],"gpt_icon":0},{"id":"2608184742","title":"双鹭药业：度拉糖肽注射液已经申报上市即将受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608184742","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608184742?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:06","pubTimestamp":1770102387,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：司美格鲁肽口服药即将获批，贵司的度拉糖肽和利拉鲁肽迟迟未能申报，是否考虑放弃申报，从而节约研发费用花在落后产品上。双鹭药业回复：您好，度拉糖肽注射液已经申报上市即将受理，注册检验已通过。如有最新情况公司会适时沟通。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002038"],"gpt_icon":0},{"id":"2608807833","title":"异动快报：双鹭药业（002038）2月2日9点33分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608807833?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:36","pubTimestamp":1769996194,"startTime":"0","endTime":"0","summary":"证券之星2月2日盘中消息，9点33分双鹭药业（002038）触及跌停板。其所属行业化学制药目前下跌。领涨股为北陆药业。该股为长寿药NMN，疫苗，创新药概念热股。1月30日的资金流向数据方面，主力资金净流入350.52万元，占总成交额1.68%，游资资金净流入843.09万元，占总成交额4.04%，散户资金净流出1193.61万元，占总成交额5.71%。近5日资金流向一览见下表：双鹭药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200004601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0239","BK0188"],"gpt_icon":0},{"id":"2588702547","title":"双鹭药业：奥司他韦订单数量有所增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702547","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702547?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:51","pubTimestamp":1764636675,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业(002038)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司有生产用于治疗流感的奥斯他韦吗！现在产量如何？双鹭药业回复：您好，目前奥司他韦订单数量有所增加，其与其他抗流感类药物的具体销售情况公司也在密切关注。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002038"],"gpt_icon":0},{"id":"2588702555","title":"双鹭药业：截至2025年9月30日股东总户数为54,779","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702555?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:48","pubTimestamp":1764636493,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业(002038)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，截至2025年11月20日，公司的股东人数是多少？谢谢。双鹭药业回复：您好, 公司会在定期报告中披露股东人数变化，截至2025年9月30日，公司股东总户数为54,779。谢谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002038"],"gpt_icon":0},{"id":"2581925888","title":"双鹭药业：参股公司上市股价上涨计入当期利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2581925888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581925888?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:51","pubTimestamp":1762519899,"startTime":"0","endTime":"0","summary":"证券之星消息，双鹭药业11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，贵公司参股的长风药业和轩竹生物比成本价浮盈3个亿，这个钱算4季度贵公司利润吗？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700036549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","002038"],"gpt_icon":0},{"id":"2581720411","title":"双鹭药业：11月4日高管梁淑洁增持股份合计100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581720411","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581720411?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347701,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月5日市场公开信息、上市公司公告及交易所披露数据整理，双鹭药业最新董监高及相关人员股份变动情况：2025年11月4日公司董秘,董事梁淑洁共增持公司股份100.0股，占公司总股本为0.0001%。双鹭药业近半年内的董监高及核心技术人员增减持详情如下：双鹭药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出816.95万，融资余额减少；融券净流入2.65万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500039016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0239","BK0188"],"gpt_icon":0},{"id":"2579390999","title":"双鹭药业：10月28日高管梁淑洁减持股份合计3.51万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579390999","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579390999?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:01","pubTimestamp":1761742900,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月29日市场公开信息、上市公司公告及交易所披露数据整理，双鹭药业最新董监高及相关人员股份变动情况：2025年10月28日公司董秘,董事梁淑洁共减持公司股份3.51万股，占公司总股本为0.0034%。双鹭药业近半年内的董监高及核心技术人员增减持详情如下：双鹭药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出941.3万，融资余额减少；融券净流入0.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900042610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2578459952","title":"双鹭药业：10月27日高管梁淑洁减持股份合计34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2578459952","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578459952?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:01","pubTimestamp":1761656481,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月28日市场公开信息、上市公司公告及交易所披露数据整理，双鹭药业最新董监高及相关人员股份变动情况：2025年10月27日公司董秘,董事梁淑洁共减持公司股份34.0万股，占公司总股本为0.0331%。双鹭药业近半年内的董监高及核心技术人员增减持详情如下：双鹭药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出544.71万，融资余额减少；融券净流入2.33万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800040620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002038"],"gpt_icon":0},{"id":"2578977674","title":"双鹭药业（002038）2025年三季报简析：净利润同比增长943.1%，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578977674","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578977674?lang=zh_cn&edition=full","pubTime":"2025-10-28 06:04","pubTimestamp":1761602671,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期双鹭药业发布2025年三季报。截至本报告期末，公司营业总收入4.59亿元，同比下降15.13%，归母净利润1.41亿元，同比上升943.1%。按单季度数据看，第三季度营业总收入1.54亿元，同比上升3.63%，第三季度归母净利润2004.98万元，同比上升143.28%。本报告期双鹭药业存货明显上升，存货同比增幅达66.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800006387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"gpt_icon":0},{"id":"2578652502","title":"股市必读：双鹭药业(002038)股东户数5.48万户，较上期减少6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578652502","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578652502?lang=zh_cn&edition=full","pubTime":"2025-10-27 04:00","pubTimestamp":1761508845,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，双鹭药业报收于7.51元，下跌1.44%，换手率2.4%，成交量20.45万手，成交额1.54亿元。来自股本股东变化：截至2025年9月30日股东户数环比下降6.35%，户均持股上升至1.88万股，表明筹码集中度提升。股本股东变化股东户数变动近日双鹭药业披露，截至2025年9月30日公司股东户数为5.48万户，较6月30日减少3713.0户，减幅为6.35%。户均持股数量由上期的1.76万股增加至1.88万股，户均持股市值为13.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002038"],"gpt_icon":0},{"id":"2578463997","title":"双鹭药业最新公告：第三季度净利润同比增长143.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578463997","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578463997?lang=zh_cn&edition=full","pubTime":"2025-10-26 17:31","pubTimestamp":1761471075,"startTime":"0","endTime":"0","summary":"双鹭药业(002038.SZ)公告称，公司第三季度实现营业收入1.54亿元，同比增长3.63%，归属于上市公司股东的净利润为2004.98万元，同比增长143.28%。年初至报告期末，公司实现营业收入4.59亿元，同比下降15.13%，归属于上市公司股东的净利润为1.41亿元，同比增长943.10%。公司净利润大幅增长主要系报告期内公司持有的首药控股、星昊医药等交易性金融资产公允价值变动收益同比增加所致。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600010577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"gpt_icon":0},{"id":"2575566476","title":"双鹭药业最新公告：参股公司轩竹生物拟在香港联交所挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575566476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575566476?lang=zh_cn&edition=full","pubTime":"2025-10-13 16:49","pubTimestamp":1760345387,"startTime":"0","endTime":"0","summary":"双鹭药业(002038.SZ)公告称，公司参股公司轩竹生物预计于2025年10月15日正式在联交所挂牌上市，股份代号为02575.HK。本次全球发售6733.35万股，发售价格为每股11.60港元。双鹭药业预计持有其发行后总股份数的0.34%，禁售期为上市后12个月。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300016668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002038","BK0028","BK0239"],"gpt_icon":0},{"id":"2571392337","title":"双鹭药业参股公司长风药业即将登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2571392337","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571392337?lang=zh_cn&edition=full","pubTime":"2025-09-30 12:10","pubTimestamp":1759205411,"startTime":"0","endTime":"0","summary":"中访网数据  北京双鹭药业股份有限公司今日发布公告，其参股公司长风药业股份有限公司计划于2025年10月8日在香港联合交易所主板正式挂牌上市，股份代码为02652.HK。根据全球发售安排，长风药业此次共发售4119.8万股，发售价定为每股14.75港元。本次发行完成后，双鹭药业将持有长风药业约1516.57万股股份，占其发行后总股本的3.68%。根据相关会计准则，双鹭药业持有的这部分股权被分类为以公允价值计量且其变动计入当期损益的金融资产。长风药业的成功上市预计将对双鹭药业2025年度的财务状况和经营成果产生积极影响。双鹭药业所持股份自长风药业上市之日起设有12个月的禁售期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20250930/31684223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","HEXmain","BK0188","002038","02652","BK0028"],"gpt_icon":0},{"id":"2569079716","title":"双鹭药业：非独立董事辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2569079716","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569079716?lang=zh_cn&edition=full","pubTime":"2025-09-23 22:03","pubTimestamp":1758636180,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月23日晚间，双鹭药业发布公告称，公司董事会于近日收到非独立董事陈玉林先生提交的书面辞职报告。陈玉林先生因年龄原因申请辞去公司第九届董事会非独立董事、提名委员会委员职务，辞任后，陈玉林先生不再担任公司及控股子公司其他职务。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-23/doc-infrnzqh8936091.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-23/doc-infrnzqh8936091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0028","BK0188","002038"],"gpt_icon":0},{"id":"2568749949","title":"双鹭药业最新公告：董事兼董事会秘书梁淑洁拟减持不超过0.0365%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2568749949","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568749949?lang=zh_cn&edition=full","pubTime":"2025-09-17 21:00","pubTimestamp":1758114047,"startTime":"0","endTime":"0","summary":"双鹭药业(002038.SZ)公告称，公司董事兼董事会秘书梁淑洁计划在预披露公告之日起十五个交易日后的三个月内，以集中竞价交易方式减持所持公司股份合计不超过375,189股，占公司总股本比例不超过0.0365%。减持原因为个人资金需求，股份来源包括公司股票期权激励计划授予及行权、二级市场买入所获的股份以及因权益分派送转的股份。减持价格将按照减持实施时的市场价格确定。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700038599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2564812325","title":"双鹭药业：公司会正视自己的不足并改进","url":"https://stock-news.laohu8.com/highlight/detail?id=2564812325","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564812325?lang=zh_cn&edition=full","pubTime":"2025-09-01 19:09","pubTimestamp":1756724940,"startTime":"0","endTime":"0","summary":"证券日报网讯双鹭药业9月1日在互动平台回答投资者提问时表示，企业的确需要不断总结经验和教训，公司会正视自己的不足并改进。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-01/doc-infnyyue9604206.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-01/doc-infnyyue9604206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002038","BK0239","BK0028","BK0188"],"gpt_icon":0},{"id":"2562768407","title":"股市必读：双鹭药业中报 - 第二季度单季净利润同比增长285.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562768407","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562768407?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:06","pubTimestamp":1756245987,"startTime":"0","endTime":"0","summary":"截至2025年8月26日收盘，双鹭药业报收于8.12元，下跌0.37%，换手率2.65%，成交量22.57万手，成交额1.84亿元。当日关注点来自交易信息汇总：8月26日主力资金净流出1432.92万元，散户资金净流入750.6万元。来自业绩披露要点：2025年中报归母净利润达1.21亿元，同比上升309.08%，但主营收入同比下降22.24%。股本股东变化股东户数变动近日双鹭药业披露，截至2025年6月30日公司股东户数为5.85万户，较3月31日增加804.0户，增幅为1.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700007890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"gpt_icon":0},{"id":"2562585223","title":"双鹭药业(002038.SZ)发布上半年业绩，归母净利润1.21亿元，增长309.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562585223","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562585223?lang=zh_cn&edition=full","pubTime":"2025-08-25 23:00","pubTimestamp":1756134043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，双鹭药业(002038.SZ)发布2025年半年度报告，该公司营业收入为3.05亿元，同比减少22.24%。归属于上市公司股东的净利润为1.21亿元，同比增长309.08%。归属于上市公司股东的扣除非经常性损益的净利润为2600.44万元，同比减少78.42%。基本每股收益为0.12元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"双鹭药业(002038.SZ)发布上半年业绩，归母净利润1.21亿元，增长309.08%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002038"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770600045921,"stockEarnings":[{"period":"1week","weight":-0.1395},{"period":"1month","weight":-0.144},{"period":"3month","weight":-0.1293},{"period":"6month","weight":-0.1862},{"period":"1year","weight":-0.0408},{"period":"ytd","weight":-0.1045}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京双鹭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54779人(较上一季度减少65.75%)","perCapita":"15551股","listingDate":"2004-09-09","address":"北京市海淀区阜石路69号碧桐园1号楼4层","registeredCapital":"102735万元","survey":"　　北京双鹭药业股份有限公司的主营业务是基因工程及相关药物的研究开发和生产经营。公司的主要产品是替莫唑胺胶囊、来那度胺胶囊、人粒细胞刺激因子注射液、外用重组人碱性成纤维细胞生长因子重组人碱性成纤维细胞生长因子凝胶、注射用人白介素-11、注射用三氧化二砷等。国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)重点培育企业、北京市“知识产权试点单位”和4项国家“863”计划成果的产业化基地。","listedPrice":12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"双鹭药业,002038,双鹭药业股票,双鹭药业股票老虎,双鹭药业股票老虎国际,双鹭药业行情,双鹭药业股票行情,双鹭药业股价,双鹭药业股市,双鹭药业股票价格,双鹭药业股票交易,双鹭药业股票购买,双鹭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}